Literature DB >> 18519632

Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL.

Charles G Mullighan1, Richard T Williams, James R Downing, Charles J Sherr.   

Abstract

Deletions of the CDKN2A/B tumor suppressor locus and of the IKAROS and PAX5 genes that promote B-lineage development occur frequently in lymphoid, but not myeloid leukemias initiated by the BCR-ABL tyrosine kinase. Why is this the case, and how do these genetic lesions contribute to an aggressive disease that fails to durably respond to targeted kinase inhibitors?

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18519632      PMCID： PMC2732413          DOI： 10.1101/gad.1673908

Source DB:  PubMed          Journal:  Genes Dev        ISSN： 0890-9369            Impact factor:   11.361


  37 in total

1.  Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.

Authors:  Catriona H M Jamieson; Laurie E Ailles; Scott J Dylla; Manja Muijtjens; Carol Jones; James L Zehnder; Jason Gotlib; Kevin Li; Markus G Manz; Armand Keating; Charles L Sawyers; Irving L Weissman
Journal:  N Engl J Med       Date:  2004-08-12       Impact factor: 91.245

Review 2.  The biology of CML blast crisis.

Authors:  Bruno Calabretta; Danilo Perrotti
Journal:  Blood       Date:  2004-02-24       Impact factor: 22.113

3.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Authors:  Moshe Talpaz; Neil P Shah; Hagop Kantarjian; Nicholas Donato; John Nicoll; Ron Paquette; Jorge Cortes; Susan O'Brien; Claude Nicaise; Eric Bleickardt; M Anne Blackwood-Chirchir; Vishwanath Iyer; Tai-Tsang Chen; Fei Huang; Arthur P Decillis; Charles L Sawyers
Journal:  N Engl J Med       Date:  2006-06-15       Impact factor: 91.245

4.  Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis.

Authors:  Beate Gleissner; Nicola Gökbuget; Claus R Bartram; Bart Janssen; Harald Rieder; Johannes W G Janssen; Christa Fonatsch; Axel Heyll; Dimitris Voliotis; Joachim Beck; Thomas Lipp; Gerd Munzert; Jürgen Maurer; Dieter Hoelzer; Eckhard Thiel
Journal:  Blood       Date:  2002-03-01       Impact factor: 22.113

5.  Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells.

Authors:  In-kyung Park; Dalong Qian; Mark Kiel; Michael W Becker; Michael Pihalja; Irving L Weissman; Sean J Morrison; Michael F Clarke
Journal:  Nature       Date:  2003-04-20       Impact factor: 49.962

6.  Overriding imatinib resistance with a novel ABL kinase inhibitor.

Authors:  Neil P Shah; Chris Tran; Francis Y Lee; Ping Chen; Derek Norris; Charles L Sawyers
Journal:  Science       Date:  2004-07-16       Impact factor: 47.728

Review 7.  Tumor suppression by Ink4a-Arf: progress and puzzles.

Authors:  Scott W Lowe; Charles J Sherr
Journal:  Curr Opin Genet Dev       Date:  2003-02       Impact factor: 5.578

8.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.

Authors:  Neil P Shah; John M Nicoll; Bhushan Nagar; Mercedes E Gorre; Ronald L Paquette; John Kuriyan; Charles L Sawyers
Journal:  Cancer Cell       Date:  2002-08       Impact factor: 31.743

Review 9.  The BCR-ABL story: bench to bedside and back.

Authors:  Stephane Wong; Owen N Witte
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

10.  Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  M Aricò; M G Valsecchi; B Camitta; M Schrappe; J Chessells; A Baruchel; P Gaynon; L Silverman; G Janka-Schaub; W Kamps; C H Pui; G Masera
Journal:  N Engl J Med       Date:  2000-04-06       Impact factor: 91.245
View more
  48 in total

1.  The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party.

Authors:  Ilaria Iacobucci; Annalisa Lonetti; Francesca Paoloni; Cristina Papayannidis; Anna Ferrari; Clelia Tiziana Storlazzi; Marco Vignetti; Daniela Cilloni; Francesca Messa; Viviana Guadagnuolo; Stefania Paolini; Loredana Elia; Monica Messina; Antonella Vitale; Giovanna Meloni; Simona Soverini; Fabrizio Pane; Michele Baccarani; Robin Foà; Giovanni Martinelli
Journal:  Haematologica       Date:  2010-06-09       Impact factor: 9.941

2.  Immature B-cell progenitors survive oncogenic stress and efficiently initiate Ph+ B-acute lymphoblastic leukemia.

Authors:  Robert A J Signer; Encarnacion Montecino-Rodriguez; Owen N Witte; Kenneth Dorshkind
Journal:  Blood       Date:  2010-06-18       Impact factor: 22.113

3.  Adaptive Immunity to Leukemia Is Inhibited by Cross-Reactive Induced Regulatory T Cells.

Authors:  Luke S Manlove; Katherine E Berquam-Vrieze; Kristen E Pauken; Richard T Williams; Marc K Jenkins; Michael A Farrar
Journal:  J Immunol       Date:  2015-09-16       Impact factor: 5.422

4.  In vivo RNAi screening identifies Pafah1b3 as a target for combination therapy with TKIs in BCR-ABL1+ BCP-ALL.

Authors:  Eleanor R C Fiedler; Arjun Bhutkar; Emily Lawler; Rana Besada; Michael T Hemann
Journal:  Blood Adv       Date:  2018-06-12

Review 5.  Genetic events other than BCR-ABL1.

Authors:  Paolo Neviani
Journal:  Curr Hematol Malig Rep       Date:  2014-03       Impact factor: 3.952

Review 6.  Chronic myeloid leukemia: mechanisms of blastic transformation.

Authors:  Danilo Perrotti; Catriona Jamieson; John Goldman; Tomasz Skorski
Journal:  J Clin Invest       Date:  2010-07-01       Impact factor: 14.808

Review 7.  Pharmacological activation of wild-type p53 in the therapy of leukemia.

Authors:  Kensuke Kojima; Jo Ishizawa; Michael Andreeff
Journal:  Exp Hematol       Date:  2016-06-18       Impact factor: 3.084

8.  Constitutive Ras signaling and Ink4a/Arf inactivation cooperate during the development of B-ALL in mice.

Authors:  Tomasz Sewastianik; Meng Jiang; Kumar Sukhdeo; Sanjay S Patel; Kathryn Roberts; Yue Kang; Ahmad Alduaij; Peter S Dennis; Brian Lawney; Ruiyang Liu; Zeyuan Song; Jessie Xiong; Yunyu Zhang; Madeleine E Lemieux; Geraldine S Pinkus; Jeremy N Rich; David M Weinstock; Charles G Mullighan; Norman E Sharpless; Ruben D Carrasco
Journal:  Blood Adv       Date:  2017-11-21

9.  Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL.

Authors:  Iris Appelmann; Cory D Rillahan; Elisa de Stanchina; Gregory Carbonetti; Chong Chen; Scott W Lowe; Charles J Sherr
Journal:  Blood       Date:  2014-12-12       Impact factor: 22.113

10.  Aging and cancer resistance in lymphoid progenitors are linked processes conferred by p16Ink4a and Arf.

Authors:  Robert A J Signer; Encarnacion Montecino-Rodriguez; Owen N Witte; Kenneth Dorshkind
Journal:  Genes Dev       Date:  2008-11-15       Impact factor: 11.361
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.